Private company

Innovation1 Biotech Inc.

Innovation1 Biotech Inc. is an American pharmaceutical preparations company based in Rockaway.¹

Last updated Oct 20, 2026.

Overview

IndustryPharmaceutical Preparations¹
HeadquartersRockaway, New Jersey¹
Incorporated inNV²
Business address179 Rte 46W, Suite 15 #147, Rockaway, Nj 07866²
Filer categoryNon-accelerated filer, Smaller reporting company²
Legal formCorporation

See how the biggest companies compare on our leaderboards

Innovation1 Biotech Inc. (the "Company" or "we") was incorporated under the laws of the State of Nevada. The Company currently has no operations and is evaluating a number of strategic alternatives including, but not limited to, seeking to acquire a new business in the United States, including potentially by means of a reverse merger with an operating entity. We have not generated revenues in fiscal 2022 or fiscal 2023 and do not expect to do so in the short-term.³ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

-$620.2KFree cash flow⁴

Financial statements

Revenue⁵⁶⁷⁸⁴$0 in 2023

Gross profit⁵⁶⁷⁸⁴$0 in 2023−100% since 2018

Operating income⁵⁶⁷⁸⁴-$1.4M in 2023+214% since 2018

Net income⁹⁵⁶⁷⁸⁴-$6.0M in 2023+16604% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Revenue		$16.8K⁵	$79.2K⁶	$1.2K⁷	$3.1K⁸	$0⁴	$0⁴
Cost of revenue		$81.0K⁵	$89.2K⁶	$3.0K⁷	$1.4K⁸	$0⁴	$0⁴
Gross profit		-$64.3K⁵	-$10.0K⁶	-$1.8K⁷	$1.7K⁸	$0⁴	$0⁴
Research and development					$0⁸	$201.2K⁴	$15.0K⁴
Operating expenses						$5.2M⁴	$1.4M⁴
Operating income		-$436.1K⁵	-$626.7K⁶	-$216.9K⁷	-$258.4K⁸	-$5.2M⁴	-$1.4M⁴
Interest		$1.5K⁵	$587⁵			$5.5K⁴	$251.8K⁴
Net income	-$35.9K⁹	-$975.5K⁵	-$170.1K⁶	-$2.6M⁷	$1.0M⁸	-$40.9M⁴	-$6.0M⁴
Earnings per share					$5.53⁸	-$2.73⁴	-$0.70⁴
Shares (weighted, basic)						15.2M shares⁴	20.2M shares⁴

Total assets¹²⁵⁶⁷⁸⁴$76.0K in 2023+2590% since 2017

Total liabilities⁹⁸⁴$3.5M in 2023+4472% since 2017

Shareholders’ equity⁵⁶⁷⁸⁴-$3.4M in 2023+25736% since 2017

Cash⁵⁶⁷⁸⁴$49.8K in 2023+199296% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Cash	$25⁵	$774.5K⁶	$19.0K⁷	$17.9K⁷	$137.5K⁸	$156.5K⁸	$49.8K⁴
Inventory						$0⁸
Current assets	$25¹²	$858.0K⁵	$248.1K⁶	$202.1K⁷	$168.5K⁸	$287.0K⁴	$72.7K⁴
Property, plant and equipment						$2.6K⁴	$1.6K⁴
Total assets	$2.8K¹²	$862.7K⁵	$256.4K⁶	$208.6K⁷	$181.9K⁸	$44.0M⁴	$76.0K⁴
Accounts payable						$106.2K⁴	$349.3K⁴
Current liabilities	$16.1K¹²	$686.9K⁵	$224.1K⁶	$2.9M⁷	$406.7K⁸	$29.8M⁴	$3.3M⁴
Long-term liabilities						$11.3M⁴	$219.0K⁴
Total liabilities	$76.7K⁹				$406.7K⁸	$41.1M⁴	$3.5M⁴
Retained earnings						-$44.6M⁴	-$58.6M⁴
Shareholders’ equity	-$13.3K⁵	$175.9K⁶	$32.4K⁷	-$2.9M⁸	$44.1M⁴	$2.1M⁴	-$3.4M⁴
Shares outstanding	132.6M shares⁹	132.6M shares¹²	135.5M shares⁵	57.6M shares⁶	20.0M shares⁷	20.0M shares⁸	20.5M shares⁴

Cash from operations⁹⁵⁶⁷⁸⁴-$620.2K in 2023+952% since 2017

Capital spending¹²⁸⁴$0 in 2023

Free cash flow⁵⁸⁴-$620.2K in 2023+39% since 2018

Share buybacks⁹⁷$0 in 2021−100% since 2017

Fiscal year	2017	2018	2019	2020	2021	2022	2023
Cash from operations	-$59.0K⁹	-$442.6K⁵	-$775.9K⁶	-$410.2K⁷	-$30.4K⁸	-$3.1M⁴	-$620.2K⁴
Depreciation and amortization						$523⁴	$1.0K⁴
Stock-based compensation						$0⁴	$80.5K⁴
Capital spending		$2.5K¹²			$0⁸	$3.1K⁴	$0⁴
Free cash flow		-$445.0K			-$30.4K	-$3.1M	-$620.2K
Cash from investing						-$853.1K⁴	$0⁴
Share buybacks	-$5.0K⁹			$80.0K⁷	$0⁷
Cash from financing						$4.0M⁴	$513.6K⁴

Compare Innovation1 Biotech Inc. with another company

What it owns

What Innovation1 Biotech Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Item	Latest	A year before	Change
Property and equipment, net	$1.6K⁴ Aug 31, 2023	$2.6K⁴ Aug 31, 2022	−40.0%
Finance-lease assets	$0⁴ Aug 31, 2023	$482.1K⁴ Aug 31, 2022	−100.0%
Operating-lease assets (leased space)	$0⁴ Aug 31, 2023	$482.1K⁴ Aug 31, 2022	−100.0%

Intangibles and goodwill

Item	Latest	A year before	Change
Trademarks and trade names (indefinite-lived)	$1.7K⁴ Aug 31, 2023	$1.7K⁴ Aug 31, 2022	0%

Leadership

Who has led Innovation1 Biotech Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

20202025

Chief executive officerKnuettel Francis Ii. Feb 4, 2025 to Feb 4, 2025¹³
Chief executive officerDarren Long Oct 24, 2017 to Oct 24, 2017¹⁴
ChairKnuettel Francis Ii. Feb 4, 2025 to Feb 4, 2025¹³
PresidentTimothy Orr Oct 24, 2017 to Oct 24, 2017¹⁵
Chief financial officerSamuel J. Knipper Mar 3, 2025 to Mar 3, 2025¹⁶

Board members and other officers (5)

Pres, Secretary & TreasurerTimothy Orr Sep 13, 2018 to Sep 13, 2018¹⁷
TreasurerBrian Martinho Oct 24, 2017 to Oct 24, 2017¹⁸
Board memberBrian Martinho Oct 24, 2017 to Oct 24, 2017¹⁸
Board memberDarren Long Oct 24, 2017 to Oct 24, 2017¹⁴
Board memberTimothy Orr Oct 24, 2017 to Sep 13, 2018¹⁵

Named in SEC Form D filings

People the company listed in its private-offering notices.

President, Acting Interim CEO and Chairman of Issuer.Frederick E. Pierce named Dec 27, 2022 to Apr 24, 2023¹⁹

Former names

GridIron BioNutrients, Inc.Nov 6, 2017 to Mar 10, 2022²
My Cloudz, Inc.Apr 13, 2015 to Feb 2, 2018²

Timeline

Feb 27, 20258-K Executive or director change²⁰
Feb 4, 2025New chief executive Knuettel Francis Ii. becomes CEO¹³
Dec 13, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²¹
Nov 7, 20238-K New debt or obligation²²
Oct 16, 20238-K New debt or obligation²³
Sep 8, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²⁴
Aug 11, 20238-K Executive or director change²⁵
Apr 24, 20238-K Entered a material agreement; Executive or director change²⁶
Dec 12, 20228-K Entered a material agreement; Executive or director change²⁷
Nov 30, 20228-K Bylaws or fiscal year changed²⁸
Nov 17, 20228-K Executive or director change²⁹
Nov 14, 20228-K Completed an acquisition or sale; Regulation FD disclosure³⁰
Oct 25, 20228-K Executive or director change³¹
Oct 24, 2017New chief executive Darren Long becomes CEO¹⁴

Filings

61 filings to the SEC since October 2021: 3 annual reports, 10 quarterly reports, 25 major events, 2 insider forms, 2 private raises, 19 other. The latest 20:

May 6, 202510-Q EDGAR
Mar 3, 20253 EDGAR
Feb 27, 20258-K EDGAR
Feb 4, 20253 EDGAR
Jan 27, 202510-Q EDGAR
Jan 27, 2025DEF 14C EDGAR
Jan 15, 2025PRE 14C EDGAR
Jan 17, 2024NT 10-Q EDGAR
Jan 17, 202410-K EDGAR
Dec 13, 20238-K EDGAR
Nov 29, 2023NT 10-K EDGAR
Nov 7, 20238-K EDGAR
Oct 16, 20238-K EDGAR
Sep 13, 202310-Q EDGAR
Sep 8, 20238-K EDGAR
Aug 11, 20238-K EDGAR
Jul 18, 2023NT 10-Q EDGAR
May 30, 202310-Q EDGAR
Apr 24, 20238-K EDGAR
Apr 24, 2023D EDGAR

The 61 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Money raised

Private offerings the company reported to the SEC on Form D.

Apr 13, 2023Raised $186,666 in a private offering of debt Form D: $280,000 offered in all Form D
Dec 8, 2022Raised $300,000 in a private offering of debt Form D: 3 investors so far Form D

SEC filer profile

How Innovation1 Biotech Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

Name on EDGARInnovation1 Biotech Inc.¹
CIK0001629205
Employer ID (EIN)82-2275255¹
Filer statusNon-accelerated filer<br>smaller reporting company¹
Incorporated inNevada¹
Fiscal year endsAugust 31¹
Industry code (SIC)2834 Pharmaceutical Preparations¹
SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
Business address179 Rte 46W, Suite 15 #147, Rockaway, NJ 07866¹
Phone929-459-4966¹
Shares outstanding22,470,239 as of May 6, 2025¹¹
On EDGAR sinceApr 13, 2015¹
Filings164 in all: 8-K (42), 10-Q (26), UPLOAD (15), NT 10-Q (14), 10-K (8), NT 10-K (8), 3 (6), CORRESP (6)¹
All 23 form types
DEF 14C (5), PRE 14C (5), 8-K/A (4), EFFECT (4), S-1/A (4), SC 13D (4), S-1 (3), 10-Q/A (2), D (2), 10-K/A (1), 4 (1), 424B3 (1), 8-A12G (1), POS AM (1), SC 14F1 (1)
Latest filingsAnnual report (10-K) Jan 17, 2024
Quarterly report (10-Q) May 6, 2025
Latest 8-K (8-K) Feb 27, 2025

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARInnovation1 Biotech Inc. filings on SEC EDGAR
2
SEC EDGARInnovation1 Biotech Inc. filings on SEC EDGAR
3
SEC EDGARInnovation1 Biotech Inc. annual report, Item 1 (Business)
4
SEC EDGARInnovation1 Biotech Inc. 10-K for fiscal 2023
5
SEC EDGARInnovation1 Biotech Inc. 10-K for fiscal 2018
6
SEC EDGARInnovation1 Biotech Inc. 10-K for fiscal 2019
7
SEC EDGARInnovation1 Biotech Inc. 10-K for fiscal 2020
8
SEC EDGARInnovation1 Biotech Inc. 10-K for fiscal 2021
9
SEC EDGARInnovation1 Biotech Inc. 10-K for fiscal 2017
10
SEC EDGARInnovation1 Biotech Inc. 10-Q for fiscal 2023
11
SEC EDGARInnovation1 Biotech Inc. 10-Q for fiscal 2024
12
SEC EDGARInnovation1 Biotech Inc. 10-K for fiscal 2017
13
SEC EDGARKnuettel Francis Ii., Chief executive officer
14
SEC EDGARDarren Long, Chief executive officer
15
SEC EDGARTimothy Orr, President
16
SEC EDGARSamuel J. Knipper, Chief financial officer
17
SEC EDGARTimothy Orr, Pres, Secretary & Treasurer
18
SEC EDGARBrian Martinho, Treasurer
19
SEC EDGARInnovation1 Biotech Inc. Form D naming Frederick E. Pierce
20
SEC EDGARExecutive or director change
21
SEC EDGAREntered a material agreement; New debt or obligation; Unregistered sale of shares
22
SEC EDGARNew debt or obligation
23
SEC EDGARNew debt or obligation
24
SEC EDGAREntered a material agreement; New debt or obligation; Unregistered sale of shares
25
SEC EDGARExecutive or director change
26
SEC EDGAREntered a material agreement; Executive or director change
27
SEC EDGAREntered a material agreement; Executive or director change
28
SEC EDGARBylaws or fiscal year changed
29
SEC EDGARExecutive or director change
30
SEC EDGARCompleted an acquisition or sale; Regulation FD disclosure
31
SEC EDGARExecutive or director change